EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

UBQLN4 Is a Prognostic Biomarker in Intrahepatic Cholangiocarcinoma That Is Associated with Cisplatin Resistance

Kodai Abe, Kelly Chong iD, Yuta Abe iD, Minoru Kitago iD, Motonori Edanami, Yosuke Uematsu, Yohei Masugi, Akihisa Ueno iD, Matias A Bustos iD, Anton J Bilchik iD, Yosef Shiloh iD, Yuko Kitagawa und 1 weitere

Cells · 2026

DOI: 10.3390/cells15181697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Kodai Abe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PH…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Cisplatin, Drug Resistance, Neoplasm, Biomarkers, Tumor. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Mariam and Sheldon Adelson Medical Research Foundation, Nakayama Foundation for Human Science, Cori foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intrahepatic cholangiocarcinoma (iCCA) is an aggressive biliary tract malignancy with limited treatment options and poor prognosis. Platinum-based drugs are one of the major therapies; however, resistance remains a major therapeutic challenge. Ubiquilin-4 (UBQLN4), a ubiquitin-binding protein implicated in cancer progression and DNA damage responses, is located at chromosome 1q22, a region recurrently amplified in several cancers. We investigated the clinical and functional relevance of UBQLN4 in iCCA.

Methods

Public datasets (TCGA-CHOL and GSE107943) were analyzed to identify genomic alterations and UBQLN4 expression in iCCA. UBQLN4 mRNA expression was evaluated in an independent clinical cohort and correlated with patient outcomes. Functional studies using iCCA cell lines and three-dimensional spheroid models examined the role of UBQLN4 in cisplatin resistance.

Results

Chromosome 1q22, containing UBQLN4, was among the recurrently amplified regions in TCGA-CHOL. UBQLN4 mRNA expression correlated with copy number amplification and was significantly higher in iCCA than in normal liver tissue in both datasets. In the validation cohort, higher UBQLN4 mRNA expression was associated with shorter recurrence-free survival (p = 0.025) and remained associated with shorter recurrence-free survival after adjustment for clinicopathological factors (HR = 2.44; 95% CI 1.14–5.20; p = 0.022). Higher UBQLN4 expression was also associated with poorer pathological response to cisplatin-containing neoadjuvant chemotherapy. In iCCA cell lines, UBQLN4 knockdown increased cisplatin sensitivity, whereas cisplatin-resistant derivatives showed increased UBQLN4 expression.

Conclusions

Elevated UBQLN4 expression is associated with adverse clinical outcomes and reduced response to cisplatin-containing chemotherapy in iCCA, while functional studies support a potential role for UBQLN4 in modulating cisplatin sensitivity. These findings identify UBQLN4 as a potential biomarker and therapeutic candidate that warrants further independent and prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaCisplatinDrug Resistance, NeoplasmBiomarkers, TumorBile Duct NeoplasmsCell Cycle ProteinsAdaptor Proteins, Signal TransducingHumansPrognosisCell Line, TumorGene Expression Regulation, NeoplasticFemaleMaleCarrier ProteinsNuclear Proteins

Stichwörter der Autor:innen

CNVUBQLN4cisplatinintrahepatic cholangiocarcinomaneoadjuvant chemotherapy

Substanzen

CisplatinBiomarkers, TumorUBQLN4 protein, humanCell Cycle ProteinsAdaptor Proteins, Signal TransducingCarrier ProteinsNuclear Proteins

Autor:innen und Institutionen

  • Department of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.
  • Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
  • Department of Pathology, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
  • Department of Pathology, Tokai University School of Medicine, Isehara 259-1193, Kanagawa, Japan.
  • Division of Diagnostic Pathology, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan.
  • Department of Translational and Precision Medicine, Saint John's Cancer Institute (SJCI), Saint John's Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA.

ORCID-Profile: Kelly Chong, Yuta Abe, Minoru Kitago, Akihisa Ueno, Matias A Bustos, Anton J Bilchik, Yosef Shiloh

Förderung

  • Dr. Mariam and Sheldon Adelson Medical Research Foundation
  • Nakayama Foundation for Human Science
  • Cori foundation

Zitieren

APA

Abe, K., Chong, K., Abe, Y., Kitago, M., Edanami, M., Uematsu, Y., Masugi, Y., Ueno, A., Bustos, M. A., Bilchik, A. J., Shiloh, Y., Kitagawa, Y., & Hoon, D. S. B. (2026). UBQLN4 Is a Prognostic Biomarker in Intrahepatic Cholangiocarcinoma That Is Associated with Cisplatin Resistance. Cells. https://doi.org/10.3390/cells15181697

Vancouver

Abe K, Chong K, Abe Y, Kitago M, Edanami M, Uematsu Y, et al. UBQLN4 Is a Prognostic Biomarker in Intrahepatic Cholangiocarcinoma That Is Associated with Cisplatin Resistance. Cells. 2026. doi:10.3390/cells15181697

BibTeX
@article{Abe2026,
  author = {Abe, Kodai and Chong, Kelly and Abe, Yuta and Kitago, Minoru and Edanami, Motonori and Uematsu, Yosuke and Masugi, Yohei and Ueno, Akihisa and Bustos, Matias A and Bilchik, Anton J and Shiloh, Yosef and Kitagawa, Yuko and Hoon, Dave S B},
  title = {UBQLN4 Is a Prognostic Biomarker in Intrahepatic Cholangiocarcinoma That Is Associated with Cisplatin Resistance},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15181697}
}
Kostenlos starten →